Beximco Pharma reports higher EPS

Consolidated earnings per share (EPS) was Tk2.22 for January-March 2020 as against Tk1.84 for the same period of last year, registering a 21.5% growth in earnings

Both earnings and profits of Beximco Pharmaceuticals Limited increased in the first quarter of this year, although its export fell by 4.9% during the period.

According to an official disclosure posted by the company on Dhaka Stock Exchange (DSE) website, consolidated earnings per share (EPS) was Tk2.22 for January-March 2020 as against Tk1.84 for the same period of last year, registering a 21.5% growth in earnings.

Spike in domestic sales was the major reason for shooting up the earnings of the drug maker, officials concerned have said.

In the first nine months of FY20 (July’19-March’20), the company’s consolidated EPS stood at Tk6.48, as against Tk5.51 for the same period of last year.

A recent study by LankaBangla Investment Ltd revealed that local players dominate Bangladesh’s pharmaceutical market. The Square Pharmaceuticals holds 17.73% of market share, while Incepta holds 10.21%, Beximco 8.39%, Opsonin 5.54%, Renata 4.97%, Healhtcare Pharma 4.57%, ACI 4.43%, Aristopharma 4.38%, Eskayef 4.36%, and Acme holds 3.91%.